Message Text

UNCLASSIFIED

PAGE 01 TOKYO 02614 280717Z

2.1

ACTION HEW-06

INFO OCT-01 ARA-10 EA-10 ISO-00 MED-03 TRSE-00 OES-05

NSF-02 USPS-01 NAS-01 FTC-01 CIAE-00 INR-07 NSAE-00

EB-07 /054 W

----- 091383

R 280659Z FEB 75 FM AMEMBASSY TOKYO TO SECSTATE WASHDC 8321 INFO AMEMBASSY MEXICO CITY

UNCLAS TOKYO 2614

E.O. 11652: N/A TAGS: CASC: MED

SUBJECT: CANCER VACCINE: DRS. MARUYAMA & FUJITA

REF: TOKYO 2603

- 1. POST IS RECEIVING NUMEROUS PRESSING INQUIRIES FROM US CONCERNING A NEW VACCINE FOR TREATMENT OF CANCER DEVELOPED AND USED BY DRS. MARUYAMA & FUJITA IN TOKYO. ALTHOUGH PERIODICALS THROUGHT WORLD HAIL SERUM AS A WONDER DRUG, IT HAS NOT BEEN LICENSED FOR COMMERCIAL PRODUCTION IN THE USA OR JAPAN.
- 2. DR. FUJITA, WHO SPEAKS FLUENT ENGLISH, IS DELUGED WITH INTERNATIONAL PHONE CALLS AND REQUESTS FOR SERUM. HE WILL MAIL IT TO INTERESTED PARTIES FOR A DONATION OF \$20. SINCE IT IS NOT YET APPROVED, SERUM MAY BE CONFISCATED BY CUSTOMS OFFICIALS. HOWEVER, FUJITA SAYS CANADIAN AND MEXICAN EMBASSIES IN TOKYO HAVE MAILED QUANTITIES THRU THEIR DIPLOMATIC POUCHES. AMERICANS WHO CONTACT FUJITA WILL PROBABLY IN TURN CONTACT EMBASSY FOR ASSISTANCE. ALSO IF CLINICS IN MEXICO HAVE ACCESS TO SERUM, AMEMBASSY MEXICO CITY AND BOARDER CONSULATES, CAN EXPECT BOMBARDMENT OF INQUIRIES.

UNCLASSIFIED

UNCLASSIFIED

PAGE 02 TOKYO 02614 280717Z

3. EMB HAS FELT IT ADVISABLE TO REFER CALLS FROM

US CITIZENS DIRECTLY TO DR. FUJITA, (SEE REFTEL)
SINCE EMB SHOULD NOT BE IN POSITION OF RECOMMENDING
EITHER THE SERUM OR THE PHYSICIANS WHO
DEVELOPED IT. FOR FUTURE CASES, REQUEST DEPT OPINION
ON EMB PROCEDURE. ALSO ADVICE ON WHETHER US CUSTOMS WOULD
ADMIT SHIPMENTS OF THIS SERUM.

4. DETAILED INFO FOLLOWS IN OM. HODGSON

UNCLASSIFIED

NNN

Message Attributes

Automatic Decaptioning: X Capture Date: 01 JAN 1994 Channel Indicators: n/a

Current Classification: UNCLASSIFIED Concepts: CANCER, VACCINES

Control Number: n/a Copy: SINGLE Draft Date: 28 FEB 1975 Decaption Date: 01 JAN 1960 Decaption Note: Disposition Action: n/a Disposition Approved on Date: Disposition Authority: n/a Disposition Case Number: n/a

Disposition Camment:
Disposition Date: 01 JAN 1960
Disposition Event:
Disposition History: n/a Disposition Reason: Disposition Remarks:

Document Number: 1975TOKYO02614 Document Source: CORE Document Unique ID: 00

Drafter: n/a Enclosure: n/a Executive Order: N/A Errors: N/A

Film Number: D750070-0919

From: TOKYO

Handling Restrictions: n/a

Image Path:

Legacy Key: link1975/newtext/t1975021/aaaaaaajj.tel Line Count: 70

Locator: TEXT ON-LINE, ON MICROFILM Office: ACTION HEW Original Classification: UNCLASSIFIED Original Handling Restrictions: n/a Original Previous Classification: n/a Original Previous Handling Restrictions: n/a

Page Count: 2

Previous Channel Indicators: n/a
Previous Classification: n/a Previous Handling Restrictions: n/a
Reference: 75 TOKYO 2603
Review Action: RELEASED, APPROVED
Review Authority: ElyME

Review Comment: n/a Review Content Flags: Review Date: 29 MAY 2003

Review Event:

Review Exemptions: n/a
Review History: RELEASED <29 MAY 2003 by BrownAM>; APPROVED <14 JAN 2004 by ElyME>

Review Markings:

Margaret P. Grafeld Declassified/Released US Department of State EO Systematic Review 05 JÚL 2006

Review Media Identifier: Review Referrals: n/a Review Release Date: n/a Review Release Event: n/a **Review Transfer Date:** Review Withdrawn Fields: n/a

Secure: OPEN Status: NATIVE

Subject: CANCER VACCINE: DRS. MARUYAMA & FUJITA TAGS: CASC, AMED, (FUJITA), (MARUYAMA)
To: STATE

Markings: Margaret P. Grafeld Declassified/Released US Department of State EO Systematic Review 05 JUL 2006